News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,785 Results
Type
Article (13811)
Company Profile (101)
Press Release (251873)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88063)
Career Advice (465)
Deals (15344)
Drug Delivery (67)
Drug Development (36613)
Employer Resources (49)
FDA (6297)
Job Trends (6201)
News (150255)
Policy (14044)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (441)
Accelerated approval (2)
Adcomms (6)
Allergies (33)
Alliances (23231)
ALS (36)
Alzheimer's disease (393)
Antibody-drug conjugate (ADC) (41)
Approvals (6333)
Artificial intelligence (107)
Autoimmune disease (9)
Automation (4)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (40)
Bladder cancer (20)
Brain cancer (16)
Breast cancer (78)
Cancer (612)
Cardiovascular disease (72)
Career advice (408)
Career pathing (12)
CAR-T (22)
Cell therapy (88)
Cervical cancer (4)
Clinical research (30933)
Collaboration (344)
Compensation (155)
Complete response letters (17)
COVID-19 (757)
CRISPR (20)
C-suite (124)
Cystic fibrosis (37)
Data (639)
Denatured (15)
Depression (9)
Diabetes (81)
Diagnostics (1319)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (61)
Drug pricing (65)
Drug shortages (12)
Duchenne muscular dystrophy (36)
Earnings (32144)
Editorial (12)
Employer branding (4)
Employer resources (43)
Events (37516)
Executive appointments (392)
FDA (6718)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (215)
Gene editing (38)
Generative AI (9)
Gene therapy (100)
GLP-1 (349)
Government (1301)
Grass and pollen (3)
Guidances (16)
Healthcare (3564)
Huntington's disease (4)
IgA nephropathy (11)
Immunology and inflammation (34)
Indications (14)
Infectious disease (792)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (47)
Interviews (59)
IPO (5877)
IRA (29)
Job creations (2051)
Job search strategy (373)
Kidney cancer (6)
Labor market (12)
Layoffs (180)
Leadership (3)
Legal (3433)
Liver cancer (19)
Lung cancer (82)
Lymphoma (55)
Machine learning (1)
Management (16)
Manufacturing (158)
MASH (32)
Medical device (1276)
Medtech (1278)
Mergers & acquisitions (9676)
Metabolic disorders (262)
Multiple sclerosis (21)
NASH (14)
Neurodegenerative disease (24)
Neuropsychiatric disorders (8)
Neuroscience (578)
NextGen: Class of 2025 (1586)
Non-profit (593)
Northern California (713)
Now hiring (8)
Obesity (150)
Opinion (119)
Ovarian cancer (21)
Pain (51)
Pancreatic cancer (14)
Parkinson's disease (46)
Partnered (7)
Patents (117)
Patient recruitment (29)
Peanut (10)
People (28961)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8051)
Phase II (13090)
Phase III (11742)
Pipeline (445)
Policy (71)
Postmarket research (1401)
Preclinical (3221)
Press Release (25)
Prostate cancer (46)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (168)
Real estate (2637)
Recruiting (17)
Regulatory (10119)
Reports (14)
Research institute (565)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (8)
Schizophrenia (37)
Series A (37)
Series B (13)
Service/supplier (3)
Sickle cell disease (32)
Southern California (726)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1629)
State (2)
Stomach cancer (3)
Supply chain (32)
Tariffs (26)
The Weekly (30)
United States (7261)
Vaccines (153)
Venture capitalists (14)
Weight loss (100)
Women's health (8)
Worklife (3)
Date
Today (78)
Last 7 days (202)
Last 30 days (907)
Last 365 days (11795)
2025 (3625)
2024 (12503)
2023 (14250)
2022 (19557)
2021 (20069)
2020 (19032)
2019 (14887)
2018 (11713)
2017 (13888)
2016 (13130)
2015 (15474)
2014 (12419)
2013 (10595)
2012 (11395)
2011 (11925)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (55)
Arkansas (3)
Asia (20134)
Australia (2616)
California (1731)
Canada (911)
China (239)
Colorado (69)
Connecticut (68)
Delaware (56)
Europe (39462)
Florida (329)
Georgia (38)
Idaho (9)
Illinois (196)
India (16)
Indiana (135)
Iowa (1)
Japan (93)
Kansas (57)
Kentucky (12)
Louisiana (1)
Maine (2)
Maryland (258)
Massachusetts (1497)
Michigan (30)
Minnesota (95)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (8)
New Hampshire (6)
New Jersey (769)
New Mexico (7)
New York (513)
North Carolina (395)
North Dakota (2)
Northern California (713)
Ohio (51)
Oklahoma (4)
Oregon (16)
Pennsylvania (445)
Puerto Rico (8)
Rhode Island (10)
South America (502)
South Carolina (2)
Southern California (726)
Tennessee (34)
Texas (233)
Utah (33)
Virginia (75)
Washington D.C. (31)
Washington State (119)
Wisconsin (16)
265,785 Results for "adamis pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus
Adamis Pharmaceuticals Corporation announced the company changed its name to DMK Pharmaceuticals Corporation in order to better reflect its new strategic focus on advancing small molecules for the treatment of substance use disorders.
September 7, 2023
·
6 min read
Deals
Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
Adamis Pharmaceuticals Corporation, a commercial-stage biopharmaceutical company, announced the closing of its merger with DMK Pharmaceuticals Corporation.
May 25, 2023
·
7 min read
Deals
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
Adamis Pharmaceuticals Corporation today announced the pricing of its public offering of 5,930,000 units at a public offering price of $1.35 per unit.
August 2, 2023
·
5 min read
Biotech Beach
Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention
Adamis Pharmaceuticals Corporation today announced that Eboo Versi, MD, PhD, CEO of Adamis Pharmaceuticals is proud and excited to have participated in the White House Roundtable with Opioid Reversal Product Manufacturers, hosted by White House Office of National Drug Control Policy Director, Dr. Rahul Gupta.
June 22, 2023
·
7 min read
Business
Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert
Adamis Pharmaceuticals Corporation today announced the Company has committed to fund an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit.
July 28, 2023
·
6 min read
Business
Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.
August 21, 2023
·
10 min read
Biotech Beach
Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering
Adamis Pharmaceuticals Corporation, a commercial-stage biopharmaceutical company, announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock.
August 4, 2023
·
5 min read
Deals
Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) and DMK Pharmaceuticals, Corp. today announced that the companies have entered into an Agreement and Plan of Merger and Reorganization (the “Agreement”).
February 27, 2023
·
12 min read
Business
Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Adamis Pharmaceuticals Corporation announced financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate developments.
May 15, 2023
·
10 min read
Biotech Beach
Adamis Pharmaceuticals Announces Reverse Stock Split - May 19, 2023
Adamis Pharmaceuticals Corporation, a commercial-stage biopharmaceutical company, announced that it will effect a 1-for-70 reverse stock split of its common stock that will become effective on May 22, 2023, at 12:01 a.m., Eastern Time.
May 19, 2023
·
6 min read
1 of 26,579
Next
